Literature DB >> 21690479

Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer.

Carl van Walraven1, Dean Fergusson, Craig Earle, Nancy Baxter, Shabbir Alibhai, Blair MacDonald, Alan J Forster, Ilias Cagiannos.   

Abstract

PURPOSE: The evidence associating cancer risk with diagnostic radiation exposure is unclear. Men recovering from low-grade testicular cancer frequently undergo serial abdominal-pelvic computerized tomography (CT) scanning to monitor for recurrent disease.
METHODS: We used population-based administrative data sets to identify every incident case of testicular cancer between 1991 and 2004 in Ontario, Canada. We excluded those with previous cancer, concurrent radiation therapy, retroperitoneal lymph node dissection, or fewer than 5 years observation. Patients were observed until the occurrences of death or development of a second abdominal-pelvic malignancy or until December 31, 2009.
RESULTS: A total of 2,569 men (mean age, 34.7 years; standard deviation, 10.2) were observed for a median of 11.2 years (interquartile range [IQR], 8.3 to 14.3). During the first 5 years after diagnosis, men underwent a median of 10 computed tomography (CT) scans (IQR, 4 to 18) of the abdominal-pelvic area, and they were exposed to a median of 110 mSv of radiation from radiologic investigations (IQR, 44 to 190). After this, 14 men were diagnosed with a second abdominal-pelvic malignancy (rate, five per 10,000 patient-years observation, 95% CI, three to eight); the most common diagnoses were colorectal and kidney malignancies. Radiation exposure was not associated with an excess risk of second cancers (hazard ratio per 10 mSv increase, 0.99; 95% CI, 0.95 to 1.04). This association did not change if men observed for fewer than 5 years were included in the analysis (hazard ratio, 1.00; 95% CI, 0.96 to 1.04).
CONCLUSION: Second malignancies of the abdomen-pelvis are uncommon in men with low-grade testicular cancer. In this study, the risk of second cancer was not associated with the amount of diagnostic radiation exposure.

Entities:  

Mesh:

Year:  2011        PMID: 21690479     DOI: 10.1200/JCO.2011.34.6379

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  12 in total

1.  Small renal masses: time to standardize follow-up of low-stage renal cancer.

Authors:  Ashraf Almatar; Michael A S Jewett
Journal:  Nat Rev Urol       Date:  2013-04-30       Impact factor: 14.432

Review 2.  Radiation risks associated with serial imaging in colorectal cancer patients: should we worry?

Authors:  Jeong Suk Oh; Jonathan B Koea
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 3.  Contemporary management of early stage testicular seminoma.

Authors:  Ahmet Murat Aydin; Logan Zemp; Salim K Cheriyan; Wade J Sexton; Peter A S Johnstone
Journal:  Transl Androl Urol       Date:  2020-01

4.  Actual frequency of imaging during follow-up of testicular cancer in Israel-a comparison with the guidelines.

Authors:  Anna-Therese Lehnich; Carsten Rusner; Gabriel Chodick; Rachel Katz; Tal Sella; Andreas Stang
Journal:  Eur Radiol       Date:  2019-04-23       Impact factor: 5.315

5.  Can whole-body MRI replace CT in management of metastatic testicular cancer? A prospective, non-inferiority study.

Authors:  Solveig Kärk Abildtrup Larsen; Vibeke Løgager; Catharina Bylov; Hanne Nellemann; Mads Agerbæk; Anne Birgitte Als; Erik Morre Pedersen
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-07       Impact factor: 4.553

6.  Second malignancies in long-term testicular cancer survivors.

Authors:  D Ondrus; M Ondrusova; L Friedova
Journal:  Int Urol Nephrol       Date:  2013-10-06       Impact factor: 2.370

7.  Patients with testicular cancer undergoing CT surveillance demonstrate a pitfall of radiation-induced cancer risk estimates: the timing paradox.

Authors:  Pari V Pandharipande; Jonathan D Eisenberg; Richard J Lee; Michael E Gilmore; Ekin A Turan; Sarabjeet Singh; Mannudeep K Kalra; Bob Liu; Chung Yin Kong; G Scott Gazelle
Journal:  Radiology       Date:  2012-12-18       Impact factor: 11.105

8.  Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).

Authors:  Konstantinos Koutsoukos; Kimon Tzannis; Christos Christodoulou; Vasilios Karavasilis; Charalambos Bakoyiannis; Thomas Makatsoris; C N Papandreou; Dimitrios Pectasides; Meletios A Dimopoulos; Aristotelis Bamias
Journal:  World J Urol       Date:  2015-09-26       Impact factor: 4.226

Review 9.  Contemporary management of stage I and II seminoma.

Authors:  Peter Chung; Padraig Warde
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 10.  [Clinical stage I seminoma. Is surveillance a new therapy standard?].

Authors:  F Zengerling; J Müller; A J Schrader; M Schrader
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.